Is elevated stool zonulin family peptide a reliable marker of increased intestinal permeability?

Clinical and analytical evidence

Elevated stool zonulin family peptide (ZFP) is widely marketed in commercial functional medicine panels as a non-invasive surrogate marker of increased intestinal tight junction permeability ("leaky gut"). However, clinical evaluation demonstrates that stool ZFP levels do not reliably correlate with gold-standard functional permeability tests, such as the dual-sugar lactulose:mannitol ratio (LMR) test. In comparative studies, ZFP concentrations frequently fail to track alongside LMR results, demonstrating poor diagnostic sensitivity and specificity. Consequently, while elevated ZFP remains a plausible surrogate marker in exploratory research, it lacks the validation necessary for robust clinical decision-making.

Mechanistic explanations

The biological plausibility of the fecal ZFP assay is severely undermined by critical assay cross-reactivity and a lack of analytical specificity:

• Target identification: Independent biochemical characterizations have revealed that commercial "zonulin" enzyme-linked immunosorbent assays (ELISAs) do not actually detect pre-haptoglobin-2 (pre-HP2), the canonical zonulin protein.
• Cross-reactivity: Instead, these commercial kits primarily cross-react with and measure properdin (factor P), a structurally related protein involved in the complement activation pathway, alongside other poorly defined proteins of the zonulin family.
• Functional implications: Because properdin is released by immune cells during inflammatory cascades, elevated fecal ZFP levels may reflect generalized mucosal immune activation and microbial stimulation rather than a direct, physical breakdown of enterocyte tight junctions.

Bottom line

While elevated stool zonulin family peptide is commonly utilized as a surrogate marker for intestinal permeability, its clinical utility is highly limited by poor correlation with the gold-standard lactulose:mannitol ratio and major analytical cross-reactivity with properdin. Elevated results should be interpreted as a general sign of mucosal immune activation or microbial exposure rather than a definitive diagnosis of increased intestinal permeability.